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Abstract 
This review summarizes the most relevant articles from the field of neuro-ophthalmology 
published in the Journal of Neurology from January 2012 to July 2013. With the advent of 
video-oculography, several articles describe new applications for eye movement recordings as 
a diagnostic tool for a wide range of disorders. In myasthenia gravis, anti-Kv1.4 and anti-Lrp4 
have been characterized as promising novel autoantibodies for the diagnosis of hitherto 
‘seronegative’  myasthenia  gravis. Several articles address new diagnostic and therapeutic 
approaches to neuromyelitis optica (NMO), which further sharpen its profile as a distinct 
entity. 4-aminopyridine has become a standard therapeutic for patients with cerebellar 
downbeat nystagmus. Finally, revised diagnostic criteria have been proposed for chronic 
relapsing inflammatory optic neuropathy (CRION) based on a careful literature review over 
the last decade.  
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Introduction 
The eclectic field of neuro-ophthalmology keeps evolving rapidly. In this article we are 
summarizing the most relevant publications in the field published in the Journal of Neurology 
from January 2012 to July 2013. The review is divided into sections about the use of eye 
movement measurements as a probe of disease, novel autoantibodies for the diagnosis of 
myasthenia gravis, neuromyelitis optica (NMO) and chronic relapsing inflammatory optic 
neuropathy (CRION) and the therapeutic use of 4-aminopyridine. 
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Eye movements as a probe of disease 
 
The examination of eye movements is a rich source of clinical information to neuro-
ophthalmologists [1]. Thanks to detailed knowledge of the underlying neurophysiological 
circuits in the brainstem, eye movements provide precise information about the localization of 
disease and often valuable clues about its etiology. With the advent of video-oculography, the 
quantitative analysis of eye movements now becomes readily accessible to clinics. 
 
Tseng et al. devised a universally applicable patient screening tool based on automated 
analysis of natural viewing eye movements [2]. The participants simply had to watch 
television while their eye movements were recorded with a head-mounted video-based eye 
tracker. The eye movements were then analyzed for ocular motor features such as saccade 
metrics, as well as visual attention based on saliency maps. The investigators analyzed patient 
populations  from  two  different  age  groups:  elderly  people  with  Parkinson’s  disease  as well as 
children with attention deficit hyperactivity disorder (ADHD) and fetal alcohol spectrum 
disorder (FASD). Based on eye movement recordings from only 15 min of video, the method 
was  able  to  distinguish  patients  with  Parkinson’s  from  age-matched controls with an accuracy 
of 89.6 % and ADHD versus FASD children  with  77.3%  accuracy.  While  in  Parkinson’s  the 
distinction was made based on ocular motor features, ADHD and FASD children were 
distinguished based on visual attention features. The patient-friendly nature of this automated 
test makes it a promising screening tool for large populations. 
 
In a population-based incidence cohort, Linder et al. looked at eye movements in patients with 
newly diagnosed Parkinson syndrome before treatment [3]. They examined 105 patients with 
Parkinson’s  disease,  11  patients with progressive supranuclear palsy (PSP) and 19 patients 
with multiple system atrophy with predominant Parkinsonism (MSA-P). The diagnosis was 
established by a movement disorder specialist and supported by single-photon emission 
computed tomography (FP-CIT SPECT). Analysis of square-wave jerks, horizontal and 
vertical saccades and smooth pursuit revealed pathological ocular motor function in all patient 
groups. The ocular motor testing, however, could not reliably differentiate different subtypes 
of Parkinson syndrome early in the course of the disease. Nevertheless, some features, such as 
slow vertical saccade velocity or low smooth pursuit gain, were found to be indicative of PSP. 
 
Ong and colleagues developed Read-Right, a free web-based application (see 
www.readright.ucl.ac.uk) to improve reading in patients with right-sided hemianopia [4]. 
First, the web application automatically assessed the visual field of the patients. Then reading 
speed was measured with six standardized paragraphs of static text at baseline and after every 
5 hours of training. Reading training consisted of freely chosen leftward scrolling text that 
could be adjusted in speed and color. The rationale of the therapy was to induce involuntary 
saccades  into  the  patient’s  blind  right hemifield as a strategy to improve reading when 
returning to normal, static text. With this paradigm, the authors could demonstrate a 
significant, training-dependent improvement of reading speeds of up to 46% after 20 hours of 
training. The free website provides a promising approach to deliver reading training to the 
home of patients when rehabilitation resources are scarce. 
 
Predicting consciousness recovery in acute patients with vegetative state (VS) is a diagnostic 
challenge on intensive care units (ICU). Weiss et al. investigated the prognostic value of 
caloric bedside irrigation in 26 brain-injured patients with VS [5]. They found that the 
presence of quick phases (rather than slow phases) of caloric nystagmus has a very high 
positive predictive value of 0.93 for regaining consciousness in these patients. The authors 
explain the good correlation with the close anatomical relation between the pathways of the 
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vestibulo-ocular reflex and consciousness in the brainstem. This indicator of a favorable 
outcome may be very helpful for guiding therapeutic decisions on ICU. In another study, 
Trojano et al. explored the visual tracking behavior of chronic patients with disorders of 
consciousness [6]. Their goal was to distinguish patients with VS from patients with 
minimally conscious state, who have a more favorable outcome. The authors found that 
patients with minimally conscious state fixated significantly more on presented targets, while 
fixation in patients with VS was at chance level. Quantitative analysis of visual tracking 
behavior, as proposed by the authors, may therefore be a promising tool for assessing and 
following up patients with impaired consciousness. 
 
Fatigue is one of the most common symptoms of multiple sclerosis (MS) with a substantial 
impact on the quality of life of patients. Fatigue is usually assessed with the fatigue severity 
scale (FSS), but objective measures of fatigue are lacking. Finke et al. set out to quantify 
fatigue in MS patients with a saccadic fatigue task [7]. They asked MS patients with and 
without fatigue to continuously perform saccades over a period of 10 minutes. They found 
that patients with fatigue had a significantly larger decrease of saccade peak velocity and 
amplitude than patients without fatigue. For their study they used a portable infrared eye-
movement recording device, which would allow for convenient bedside testing of fatigue in a 
clinical setting. The system, however, only  provides  ‘cyclopean’  recordings  of  the  average  
position of both eyes. As the authors acknowledge, the presence of internuclear 
ophthalmoplegia (INO), which is a frequent finding in MS, may interfere with the result in 
these patients. 
 
 
Novel myasthenia gravis autoantibodies 
 
Ocular myasthenia gravis (MG) is often a diagnostic dilemma, because autoantibodies to 
acetylcholine receptors (AChR) are negative in over 50% of cases, repetitive nerve 
stimulation of peripheral muscles has a poor sensitivity, and single fiber electromyography as 
the current gold standard is cumbersome and uncomfortable for the patients. For these 
reasons, detection of additional autoantibodies would be very helpful in bridging the 
diagnostic  gap  of  hitherto  ‘seronegative’  ocular MG. 
 
Recently, novel autoantibodies to Kv1.4 have been identified [8]. Kv1.4 is a subunit of the 
voltage-gated potassium channel (VGKC) involved in the presynaptic release of 
acetylcholine. The study has been done in a Japanese population, where the antibodies were 
associated with severe MG with bulbar involvement, myasthenic crisis, thymoma, 
myocarditis, and QT prolongation on electrocardiogram. Based on this study, Romi et al. set 
out to investigate the clinical features and serological associations of anti-Kv1.4 antibodies in 
a Caucasian MG population [9]. They included samples from 129 myasthenia gravis patients 
with mainly ocular symptoms. They could detect anti-Kv1.4 antibodies in 17% of their 
patients, most of them women with late-onset MG. So, while in a Japanese population, anti-
Kv1.4 autoantibodies seem to be associated with severe MG and thymoma, in Caucasians the 
same antibodies are associated with mild, late-onset MG in women. To reconcile this 
disparity, the authors point out to the genetic differences between the two study populations 
as a likely explanation. 
 
Approximately 10% of patients with generalized MG have neither antibodies against AChR 
nor muscle-specific tyrosine kinase (MuSK). However, onset and progression of these so-
called double-seronegative patients is very similar to seropositive patients. As they respond 
similarly to plasma exchange and immunosuppressive therapy, the disease is likely caused by 
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another pathogenic autoantibody. Recently, autoantibodies to low-density lipoprotein 
receptor-related protein 4 (Lrp4) have been characterized in patients with AChR-negative MG 
[10]. In this Japanese population, anti-Lrp4 antibodies have been detected in only 9 out of 300 
MG patients. Based on this study, Pevzner et al. analyzed sera from 13 double-seronegative 
MG patients in a Caucasian population [11]. In contrast to the previous study, they detected 
autoantibodies against Lrp4 much more frequently in about 50% of their patients (7/13) with a 
female preponderance and rather late onset. Similar to the differences found for the anti-
Kv1.4 antibodies described above, the authors attributed the variation to the different ethnical 
background of their patients. 
 
In contrast to double-seronegative MG patients, double-seropositive patients are exceedingly 
rare with only a handful patients reported to date. Rajakulendran et al. described an interesting 
case with clinically biphasic MG with both AChR and MuSK antibodies [12]. The patient 
first presented during adolescence with bulbar predilection typical for AChR-positive MG. 
Following thymectomy she went into complete remission. 15 years later, she presented again, 
this time with severe oculobulbar, neck and respiratory muscle involvement. She then had 
several relapses that had to be treated with intravenous immunoglobulins and plasma 
exchange. At this stage, the patient was tested positive for both AchR and MuSK antibodies. 
Although the authors could not prove that the patient was MuSK-negative at initial 
presentation (as it was not tested), they conjecture from the biphasic clinical course that she 
switched from a predominantly AchR-mediated to a MuSK-mediated phenotype after 
thymectomy. Based on their experience, the authors recommend testing for MuSK antibodies 
in MG patients who relapse after thymectomy as this may substantially change their 
therapeutical approach. 
 
 
Neuromyelitis optica (NMO) and chronic relapsing inflammatory optic neuropathy 
(CRION) 
 
Neuromyelitis optica (NMO) is a rare inflammatory and demyelinating disease characterized 
by optic neuritis and longitudinally extensive transverse myelitis. Eugène Devic and his 
student Fernand Gault coined the term NMO in 1894 based on 16 patients with this rare 
association of symptoms [13]. However, Jarius et al. re-discovered an earlier, forgotten report 
from 1804 by the French pathologist and first physician to Louis XVIII, Antoine Portal 
(1742–1832), who described a patient with visual loss and spinal cord inflammation but no 
brain pathology [14]. In another paper, Jarius et al. also highlighted the seminal role of Sir 
Thomas Clifford Allbutt (1836-1925), best known as the inventor of the clinical thermometer, 
in piecing the NMO syndrome together based on three cases with the same concurrence of 
symptoms published in 1870 [15]. 
 
As NMO is a rare disease, reliable epidemiological data has been quite sparse. Previous 
studies in different ethnic groups reported variable prevalence rates between 3.2 (Japan) and 
44/million (Denmark). Jacob et al. established the epidemiology of NMO in Merseyside, 
which is a metropolitan county in North West England with the City of Liverpool as its 
headquarters [16]. The adult population of Merseyside is about 1.1 million with 94.8% 
Caucasians, which is approximately representative for the United Kingdom in general. Based 
on multiple overlapping data sources including hospital records, central anti-aquaporin 4 
(AQP4) antibody testing laboratory data and the British Neurological Surveillance Unit, they 
identified eight cases with NMO or NMO spectrum disorder indicating a prevalence of 
7.2/million with an average annual incidence rate of 0.8/million. Extrapolating to the whole 
UK population, the estimated prevalence would correspond to 365 cases with an average 
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annual incidence rate of 39 cases. The authors point out that the relatively low prevalence 
compared to other studies probably reflects genetic differences in the population studied. 
Although the authors took great care in avoiding any ascertainment bias by using overlapping 
data sources, they admit that some NMO cases may have been missed mainly because of 
misdiagnosis as multiple sclerosis (MS). Due to increasing awareness of NMO and its varied 
spectrum, the authors expect the prevalence to rise in the future.  
 
To elucidate the time course of NMO, Uzawa et al. retrospectively analyzed a Japanese cohort 
of 43 patients with a mean disease duration of 14.2 years [17]. Myelitis and optic neuritis 
were about equally frequent as initial inflammatory events (44.2% and 41.9%), while both 
together occurred in about 9.3%. Interestingly, myelitis was found to be the more frequent 
initial symptom in older patients (>50 years), whereas optic neuritis was seen more often in 
younger patients (<50 years). By the end of the observation period, 93% of the patients had 
positive anti-AQP4 antibody titers. The median interval from onset until fulfillment of the 
2006 NMO criteria [18] was 28 months, indicating the difficulty for early diagnosis of the 
disease. Based on this diagnostic delay of over 2 years, the authors highlight the need for 
early diagnostic markers or more specific criteria in order to initiate the appropriate treatment 
timely. 
 
According to the current diagnostic criteria [18], optic neuritis and myelitis are absolute 
criteria for NMO. Extension of the myelitis over three or more vertebral segments together 
with the presence of AQP4 antibodies and a brain MRI that does not meet the criteria for MS 
further supports the diagnosis of NMO. In a recent study Iorio et al. compared the clinical and 
neuroimaging characteristics of 37 patients with longitudinally extensive transverse myelitis 
[19]. 16 of their patients had positive anti-AQP4 antibodies with a higher female to male ratio 
than the negative patients. In these patients the myelitis was often accompanied by intractable 
nausea, vomiting and paroxysmal tonic spasms. This was explained by the fact that the 
inflammatory lesions extended into the brainstem more frequently involving the central grey 
matter. These distinctive clinical features may help to identify patients with NMO earlier in 
order to prompt the appropriate treatment. 
 
Despite many similarities with MS, the treatment of NMO is different. Since randomized 
controlled trials for the treatment of this rare disease are lacking, current therapeutic concepts 
are still based on expert opinion and consensus criteria [20]. While current best practice 
recommends oral treatment with azathioprine in combination with corticosteroids, the 
efficacy of cyclosporine A has not yet been evaluated in NMO. Kageyama et al. reviewed the 
clinical records of 52 patients with NMO spectrum disorders and included 22 patients for 
analysis of their treatment [21]. First, the authors confirmed the efficacy of azathioprine in 
combination with corticosteroids as a treatment for NMO. Second, they provided the first 
evidence that the combination of cyclosporine A and corticosteroids may be equally effective. 
Under treatment with cyclosporine A, they observed a significant reduction in the annual 
relapse rate as well as a decreased dose of concomitantly administered corticosteroids. In 
summary, the case series provides the first retrospective evidence for the efficacy of 
cyclosporine A in the treatment of NMO spectrum disorders, but randomized controlled 
treatment trials are warranted to confirm these results. 
 
In a case report, Juryńczyket al. reported the deleterious effect of natalizumab in a patient 
with initially unrecognized NMO [22]. The woman was diagnosed with MS at the age of 22. 
She had recurrent relapses of spastic paraparesis, sensory deficits and severe right optic 
neuritis. Over the years, she was treated with interferon ß-1a, glatiramer acetate and 
mitoxantrone. While she was in a stable condition, she was then started on natalizumab. Six 
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days after the fourth infusion, she suddenly developed a severe relapse with confusion, 
vomiting and paralysis of her left upper limb. Her brain MRI showed an extensive, non-
contrast-enhancing T2-hyperintense lesion. Negative JC virus PCR ruled out progressive 
multifocal leucencephalopathy. Based on the presence of anti-AQP4 antibodies, the patient 
was finally diagnosed with NMO according to the current criteria. Treatment with 
plasmapheresis and intravenous methylprednisolone led to clinical improvement with 
resolution of confusion after two weeks. In line with previous reports, this clinical case 
highlights that, following a few infusions, natalizumab may induce a severe relapse in patients 
with NMO. The authors therefore recommend testing for anti-AQP4 antibodies in atypical 
MS patients, especially with severe spinal and/or optic nerve involvement, before natalizumab 
initiation and in patients who develop extensive brain lesions during treatment. 
 
Horwitz et al investigated the diagnostic value of a lumbar puncture in patients with optic 
neuritis depending on the result of visual evoked potential (VEP) and MRI examination of the 
brain [23]. For this purpose, they retrospectively analyzed 437 patients who presented with 
optic neuritis without known MS prior to referral. They found that cerebrospinal fluid (CSF) 
abnormalities (elevated leucocytes, elevated IgG index or oligoclonal bands) correlated 
strongly with pathological VEP and MRI results (p < 0.0001). Vice versa, they calculated that 
patients with both normal MRI and VEP had a 96 % probability of normal CSF findings. 
From their results they concluded that the diagnostic contribution of a lumbar puncture to the 
evaluation of optic neuritis is negligible in patients with normal VEP and MRI. Therefore, the 
authors suggested that all patients with suspected optic neuritis should be evaluated with VEP 
and MRI before deciding on a lumbar puncture. 
 
Apart from NMO, the differential diagnosis of optic neuritis includes the rare entity of 
chronic relapsing inflammatory optic neuropathy (CRION), which was first described by 
Kidd et al. in 2003 [24]. In a systematic literature review, Petzold et al. now analyzed 122 
patients with CRION over the last decade [25]. They characterized it as a rare, worldwide 
disease with a peak in the fourth decade and a female preponderance. Typically, patients 
presented with bilateral simultaneous or sequential, mostly severe visual loss and at least one 
relapse. Pain at onset was reported in at least about a third of the cases and particularly 
recurrence of pain after reducing or stopping the steroids was noted as a red flag. Importantly, 
most of the patients were negative for AQP4 antibodies, suggesting that CRION is an entity 
distinct from NMO. In addition, MRI scans of the brain did not show demyelinating lesions 
typical for MS. Taken together, its etiology still remains unknown, but seems likely to be 
immune-mediated. All patients treated with methylprednisolone responded, but relapsed after 
stopping the treatment. Therefore, oral steroids had to be carefully tapered under rigorous 
follow-up to identify the individual minimal effective dose. As a consequence of the steroid-
dependency, steroid-sparing agents (azathioprine, methotrexate, cyclophosphamide or 
mycophenolate) had to be used in many cases. But as a silver lining, in the experience of the 
authors, disease activity sometimes settled over a decade. Based on their careful review with 
the key points outlined above, they proposed revised diagnostic criteria for CRION (table 1). 
Since the diagnosis of CRION based on these criteria remains mainly clinical without any 
specific blood biomarker, the authors hope for the discovery of a novel antibody, which 
would facilitate early diagnosis and adequate treatment of the disease. 
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Cerebellar downbeat nystagmus: treatment with 4-aminopyridine  
 
Hypofunction of the cerebellar flocculus causes - among other ocular motor signs - downbeat 
nystagmus (DBN) that, in turn, may lead to debilitating vertical oscillopsia. In recent years, 4-
aminopyridine (4AP), a potassium channel blocker that increases Purkinje cell excitability, 
has become a valuable therapeutic option to dampen cerebellar DBN. 4AP also prevents 
attacks in episodic ataxia type 2 and improves cerebellar gait disorders. Fampridine is the 
sustained-release form of 4AP. Only two doses per day are required and cardiac side effects 
(prolonged QTc-time) are less common than in 4AP. Fampridine is usually well tolerated by 
patients [26].  
 
In patients with ataxia-telangiectasia (A-T), which typically involves the cerebellum, Shaikh 
et al. studied the effect of 4AP on ocular motor signs [27]. 4AP reduced deficits ascribed to 
the loss of cerebellar Purkinje cells in these patients. Specifically, 4AP shortened the time 
constant of the horizontal vestibulo-ocular reflex and decreased spontaneous and periodic 
alternating nystagmus. 
 
In a patient with a right posterior vermis lesion leading to positional DBN and vertigo, 4AP 
was beneficial [28]. The lesion had caused hypofunction of the nodulus and 
flocculus/paraflocculus, as demonstrated with FDG-PET. This hypofunction was partly 
reversed by 4AP, which suggests that the cerebellar structures inhibiting the upward ocular 
drift bias were functionally restored by the substance. 
 
Another patient with a cerebellar ocular motor syndrome showed a reversal of DBN into 
upbeat nystagmus (UBN) after a test dose of fampridine [29]. Most likely, fampridine caused 
a transient over-activity of Purkinje cell neurons in this patient. This, in turn, increased the 
inhibition of superior vestibular nuclei neurons, which predominantly encode in the upward 
direction. Consequently, the eyes drifted downward leading to UBN. 
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Highlights [box with bullet points] 
 Read-Right, a free web-based application (www.readright.ucl.ac.uk) improves reading 
in patients with right-sided hemianopia [4]. 
 The presence of nystagmus fast phases after caloric irrigation predicts consciousness 
recovery in patients with vegetative state on ICU [5]. 
 Anti-Kv1.4 [9] and anti-Lrp4 [11] are promising novel autoantibodies for the 
diagnosis of hitherto  ‘seronegative’  myasthenia gravis. 
 While cyclosporine A may be effective in the treatment of NMO [21], natalizumab 
may have deleterious effects [22].  
 4-aminopyridine (4AP) and fampridine (sustained-release form of 4AP) are effective 
treatments of spontaneous and positional downbeat nystagmus resulting from 
vestibulo-cerebellar hypofunction [26,27]. 
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Table 1 
Revised diagnostic criteria for chronic relapsing inflammatory optic neuropathy (CRION) 
[25] 
 
1. History: optic neuritis and at least one relapse. 
2. Clinical: Objective evidence for loss of visual function. 
3. Labor: NMO-IgG seronegative. 
4. Imaging: Contrast enhancement of the acutely inflamed optic nerves (optic nerve 
atrophy at later stages). 
5. Treatment: Response to immunosuppressive treatment and relapse on withdrawal or 
dose reduction. 
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